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Abstract
Objectives: Diabetic cardiomyopathy (DCM) is an established complication of diabetes mellitus.
In West Virginia, the especially high incidence of diabetes and heart failure validate the necessity of
developing new strategies for earlier detection of DCM. Since most DCM patients remain
asymptomatic until the later stages of the disease when the fibrotic complications become irreversible, we aimed to explore biomarkers that can identify early-stage DCM. Methods: The patients were grouped into 4 categories based on clinical diabetic and cardiac parameters: Control,
Diabetes (DM), Diastolic dysfunction (DD), and Diabetes with diastolic dysfunction (DM+DD), the last
group being the preclinical DCM group. Results: Echocardiography images indicated severe diastolic dysfunction in patients with DD+DM and DD compared to DM or control patients. In the
DM and DM+DD groups, TNFα, isoprostane, and leptin were elevated compared to control
(p<0.05), as were clinical markers HDL, glucose and hemoglobin A1C. Fibrotic markers IGFBP7
and TGF-β followed the same trend. The Control group showed higher beneficial levels of adiponectin and bilirubin, which were reduced in the DM and DM+DD groups (p<0.05). Conclusion:
The results from our study support the clinical application of biomarkers in diagnosing early stage
DCM, which will enable attenuation of disease progression prior to the onset of irreversible
complications.
Key words: cardiomyopathy, diabetes, West Virginia, serum biomarkers.

Introduction
In recent years, diabetes mellitus (DM) has become a national health epidemic. The Centers for
Disease Control and Prevention reports that West
Virginia has one of the highest rates of diabetes in the
United States with more than 11% of the population
affected. The Framingham Heart Study revealed that
the risk of heart failure is up to 5 times higher in diabetics than non-diabetics, when controlling for other
risk factors. Diabetic Cardiomyopathy (DCM) is an

established complication of diabetes [1-6] that involves abnormal relaxation of the ventricles, referred
to as diastolic dysfunction, with concurrent hypertrophy of cardiomyocytes [6, 7]. Diastolic dysfunction
is thought to be the first functional abnormality in
DCM and can be seen in 40-60% of asymptomatic diabetic patients through echocardiographic imagining
studies [2, 6]. Diabetic patients with subclinical diastolic dysfunction have a 5-year mortality rate of 30.8%
http://www.medsci.org
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compared to 12.1% for diabetic patients with no diastolic dysfunction [4]. As DCM enters its later stage,
it progresses from diastolic dysfunction to overt stage
C heart failure with preserved ejection fraction, which
has no proven effective treatment [7], thus validating
the importance of identifying biomarkers that can
improve detection of DCM prior to the onset of irreversible complications.
Diabetes impairs glucose uptake and results in
an increase in fatty acid (FA) metabolism in cardiac
tissue [3, 8, 9]. In diabetes, decreased insulin signaling
activates transcriptional signaling pathways that induce the expression of genes involved in stimulating
FA uptake; however the uptake of FAs exceeds metabolic demand and results in triglyceride and cholesterol accumulation in the myocardium which impairs
diastolic function [8-11]. A study by McGavock et al
compared normoglycemic individuals with diabetic
patients and confirmed a positive correlation between
impaired glucose tolerance and myocardial triglyceride content and found that triglyceride accumulation
preceded the onset of ventricular dysfunction [11].
Abnormal FA metabolism also leads to depressed
levels of high-density lipoprotein (HDL) [3].
Multiple studies have established a link between
damage induced by oxidative stress and DCM [12,
13]. Damage from oxidative stress due to the chronic
mitochondrial overproduction of reactive oxygen
species (ROS) plays a crucial role in inflammation and
results in irreversible fibrosis and cardiomyocyte
death [2, 12, 14, 15]. Inflammation in the myocardium
is mediated by pro-inflammatory cytokines including
TNFα and interleukin-6 [16]. Isoprostanes are formed
by the peroxidation of polyunsaturated FAs and are
considered an accurate reflection of the extent of oxidative damage [17]. Amelioration of oxidative stress
on a molecular level can be achieved through induction of antioxidant agents, and studies have shown
that enhancing mitochondrial ROS scavenging systems mitigates diabetes-induced cardiac dysfunction
[2, 12, 18-21]. Bilirubin, a product of heme catabolism,
is a potent antioxidant and under normal physiological conditions may attenuate many ROS-derived
complications of DCM [22, 23]. Adiponectin is a
hormone secreted by adipose tissue that regulates
metabolic processes and functions as an antioxidant;
the low plasma levels of adiponectin seen in diabetes
contribute to the oxidative damage seen in DCM [24,
25].
Structurally, the progression of DCM has been
linked to cardiomyocyte hypertrophy and increased
fibrosis [26-29]. The presence of cardiomyocyte hypertrophy was supported by data from The Framingham Heart Study, which revealed left ventricular
mass was higher in diabetics compared to
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non-diabetics independent of covariates [30]. Hyperglycemia facilitates the reaction of glucose with collagen to form advanced glycation end-products (AGEs) that promote the crosslinking of collagen molecules to produce fibrosis [26]. Insulin-like growth
factor binding protein 7 (IGFBP7) is a modulator of
insulin-like growth factors, which actively regulate
insulin consumption and receptor activity [27].
IGFBP7 has been identified as a biomarker for diastolic dysfunction associated with cardiac hypertrophy, myocyte fibrosis, and vascular remodeling, and
an association exists between serum IGFBP7 levels
and echocardiographic abnormalities describing diastolic heart dysfunction independent of systolic
function [28]. In diabetics, increased ROS production
causes the subsequent release of the profibrotic
marker transforming growth factor beta (TGF-β) [29].
TGF-β levels correlate with the degree of cardiac fibrosis [26]. The reliable early detection of fibrotic
changes in DCM patients by IGFBP7 and TGF-β is
clinically pertinent since current experimental therapies designed to prevent progression of DCM include
targeting collagen deposition and fibrosis through
AGE inhibitors and AGE cross-link breakers [1, 6].
The aim of this study was to investigate a panel
of biomarkers, including fibrotic markers, antioxidants, markers of oxidative stress and a metabolic
profile that can be used to detect DCM prior to the
presentation of clinical signs. Early stage DCM is initially asymptomatic and reversible; however, DCM is
a progressive disease and at the later stage prognosis
becomes poor. Analysis of biomarkers would be a
simple, noninvasive diagnostic tool with a high predictive value for clinical use in patients with the potential to develop DCM, which would allow for the
implementation of therapeutic strategies to be started
in time to delay and mitigate the disease progression.

Materials and Methods
Patients
This study comprised of 100 patients, divided
into 4 categories based on predetermined clinical diabetic and cardiac parameters: 1. Control; 2. Diabetes
with normal diastolic function; 3. Diastolic dysfunction without diabetes; 4. Diabetes and diastolic dysfunction. Contraindications to inclusion included any
systolic dysfunction observed through echocardiography, evidence of prior myocardial infarction,
known valvular or congenital heart disease or other
significant comorbidities, including malignancy, renal
failure, or significant psychiatric illness. The study
was approved by the Ethics Committee of Cabell
Huntington Hospital, West Virginia. All of the subjects signed a written informed consent form.
http://www.medsci.org
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Table 1: Demographic Profile
Groups

Control

Age (yrs.) 41.67±11.79
Sex (M/F) 43%/57%

Diastolic
dysfunction
(DD)

Diabetes
mellitus
(DM)

Diabetes mellitus with
diastolic dysfunction
(DM+DD)

44.27±8.31
50%/50%

48±11.78 45.69±8.42
52%/48% 57%/43%

Blood Samples
Venous blood was drawn from an antecubital
vein in heparinized and Vacutainer tubes for serum
levels of TNFα, IL-6, Isoprostane, leptin, adiponectin,
bilirubin, IGFBP7, TGF-β and lipid and glucose profiles. Blood was processed after collection and serum
collected for analysis. Serum was collected by spinning down the vacutainer tube at 2000 rpm for 5
minutes at 4°C and stored at -80°C until analysis.

Analysis of Biomarkers
Serum samples frozen at -80°C were analyzed
for levels of the following biomarkers through enzyme-linked immunosorbent-assay (ELISA): TNFα,
IL-6, adiponectin and leptin (EMD Millipore, Temecula, Ca), Isoprostane (Cayman Chemical Company,
Ann Arbor, MI), bilirubin (Sigma-Aldrich, St. Louis,
MO), triglycerides (Abcam, Cambridge, MA), and
IGFBP7 and TGF-β (kits from R&D Systems, Minneapolis, MN). ELISAs were conducted in accordance to
the manufacturer’s protocol.

Echocardiography
Patients underwent echocardiography with 2D,
Doppler, and color flow imaging within the year prior
to enrollment. Studies were performed on a Philips IE
33 with an S5 transducer by one of 2 certified echo
technicians in an ICAEL- accredited laboratory.
Measurements were obtained in accordance with
guidelines set forth by the American Society of Echocardiography [31] 2D imaging was used to assess
ejection fraction (EF), septal wall thickness, posterior
wall thickness and left atrial size. Relative wall thickness was calculated with posterior and septal wall
thickness by (2×PWTd)/LVIDd [32]. Mitral valve in-

flow Doppler was recorded, including E and A waves.
Tissue Doppler was used for E’ and A’. Echocardiographic images were read by physicians who were
blinded to the rest of the study.

Statistical Analysis
Data were analyzed using Graphpad Prism 4.0.
Equal variance was assured by Bartlett’s test for each
biomarker within each of the four patient categories.
ANOVA was conducted to identify statistically significant differences in the mean serum levels for the
different biomarkers. The Tukey post-hoc test was
used to indicate which patient groups showed statistically significant differences for the biomarker level
measured.

Results
Echocardiography
All patients underwent transthoracic echocardiography to evaluate left ventricular diastolic filling
pressure. Patients were identified as normal or as
having diastolic dysfunction (DD), with DD encompassing a spectrum of severities including impaired
relaxation, pseudonormal and restrictive diastolic
dysfunction (Fig. 1). Results from echocardiographic
imaging studies were used in conjunction with the
diabetic status of the patients to establish the 4 patient
categories.

TNFα, isoprostane and IL-6 levels
TNFα, isoprostanes, and IL-6 are inflammatory
mediators that correlate with the extent of oxidative
damage in tissues. TNFα and IL-6 were found to be
elevated in DM, DD and DM+DD patients when
compared to the control group (Fig. 2A and B respectively; p < 0.05). Levels of TNFα and IL-6 were significantly higher in patients with DM+DD than the levels
found in either the patients with DM or the patients
with DD alone (p < 0.05). Patients with DM and patients with DM+DD had increased levels of isoprostane compared to the control (Fig. 2C). Additionally,
isoprostane levels in patients with DM+DD were
higher than levels observed in patients with DD alone
(p < 0.05).

Table 2: Patient Clinical Profile.
Control
DM
DD
DM+DD

BMI
23.89 (±1.01)
39.79* (±1.82)
31.42# (±2.70)
39.44* (±2.68)

Triglycerides (mg/dL)
61.12 (±11.02)
85.72 (±8.62)
92.16 (±8.10)
113.05* (±9.39)

HDL (mg/dL)
67.60 (±3.96)
43.60* (±2.04)
44.42* (±3.85)
39.50* (±1.97)

Glucose (mg/dL)
91.50 (±4.50)
186.28* (±3.97)
107.23# (±24.14)
172.9* (±13.66)

HbA1C (mg/dL)
5.20 (±0.11)
8.04* (±0.12)
5.72# (±0.50)
7.36*+ (±0.29)

Values represent means ± SEM. * p<0.05 vs Control; # p<0.05 vs DM; + p<0.05 vs DD.

http://www.medsci.org
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Figure 1: Mitral inflow velocities representing normal physiology as well as the spectrum of diastolic dysfunction. A: Normal. B: Impaired Relaxation. C:
Grade II diastolic dysfunction (pseudonormalization). D: Restrictive

Figure 2: Assay of serum concentrations of (A) TNFα, (B) IL-6 and (C) Isoprostane in Control, DM, DD and DM+DD patient groups. Values represent
means ± SEM. * p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD.

http://www.medsci.org
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Leptin, adiponectin and bilirubin levels
Leptin is an adipose-derived hormone that
stimulates energy expenditure and is proportional to
the amount of body fat. Leptin was significantly
higher in the DM, DD and DM+DD patients when
compared to the control group and was also significantly increased in the DM+DD patients when compared to the patients with DD alone (Fig. 3A; p < 0.05).
Adiponectin was significantly lower in DM, DD, and
DM+DD patients when compared to control groups
(Fig.3B). Adiponectin was also significantly decreased
in DM+DD patients when compared to patients with
DM and DD alone (p < 0.05). Bilirubin, a potent anti-
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oxidant, was found to be lowered in the DM+DD
group compared to the control (Fig. 3C; p < 0.05).

TGF-β and IGFBP7 levels
TGF-β correlates to the extent of fibrosis and
IGFBP7 has been linked to cardiomyocyte hypertrophy and fibrosis. In concordance with our hypothesis,
TGF-β levels were elevated in DM, DD and DM+DD
patients when compared to the control group (Fig. 4A;
p < 0.05). DM+DD patients did have significantly
higher TGF-β levels than the DM group alone. IGFBP7
was found to be increased in the DM, DD and
DM+DD groups compared to the control. IGFBP7 was
also higher in patients with DM+DD compared to
patients with DM or DD alone (Fig. 4B; p < 0.05).

Figure 3: Serum levels of (A) Leptin, (B) Adiponectin and (C) Bilirubin in Control, DM, DD and DM+DD patient groups determined by ELISA. Values
represent means ± SEM. * p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD.

Figure 4: Assay of serum concentrations of (A) TGF-β and (B) IGFBP7 in Control, DM, DD and DM+DD patient groups. Values represent means ± SEM.
* p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD.

http://www.medsci.org
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Elevated levels of the inflammatory cytokines
TNFα and IL-6 are associated with diabetes, and preThis study demonstrated that a panel of bivious studies have indicated their role in cardiac reomarkers in conjunction with echocardiography plays
modeling, fibrosis and cardiomyocyte apoptosis [34].
an important role in the detection of DCM prior to the
In corroboration with these findings, our study
manifestation of symptoms and irreversible complidemonstrated elevated levels of TNFα and IL-6 relacations. Our data indicated that early stage DCM can
tive to the control in DM, DD, and DM+DD patients,
be characterized by elevated levels of inflammatory
with the highest levels in DM+DD patients, supportmarkers, decreased antioxidant markers and, most
ing their utilization in the early detection of DCM and
importantly, increased levels of the fibrotic markers
amelioration of disease progression. Isoprostane, an
IGFBP7 and TGF-β. These results, which are summaestablished marker of oxidative stress [11], was inrized in the schematic diagram (Fig. 5), identified pocreased in patients with DM+DD. Our results also
tential biomarkers that can be used clinically to imdemonstrate a decreased level of the antioxidant bilprove early diagnosis of DCM.
irubin in patients with DM+DD, which supports preThe clinical parameters studied include BMI and
vious findings that bilirubin is negatively associated
levels of triglycerides, HDL, glucose and HbA1C. A
with diabetes and its complications.
comprehensive national study, which substantiates
Leptin is closely associated with obesity and its
the correlation between BMI and diabetes, found that
comorbidities [35], and was highest in patients with
individuals with diabetes were more likely to have a
DM and patients with DM+DD, which were the
high BMI [33]. In concordance with established studgroups with the highest BMIs. There is an inverse
ies, our results demonstrated elevated blood glucose
relationship between adiponectin and leptin levels,
levels and HbA1C levels in both DM patients and
with low adiponectin levels indicating metabolic and
patients with DM+DD. As expected, neither glucose
cardiovascular disease [36]. Adiponectin has antidianor HbA1C was elevated in DD patients, because DD
betic effects and antagonizes the progression of DCM
is not specific to DCM but can result from hypertenby exhibiting potent anti-hypertrophic activity in
sion, aortic stenosis, myocardial infarction, or systolic
cardiomyocytes and diminishing cardiac cell death by
heart failure [31]. Triglycerides are elevated in diainhibiting inflammation [36-38]. Consistent with prebetic patients due to an increased reliance on fatty
vious studies, our data identified decreased levels of
acid metabolism, and our data demonstrated DM+DD
adiponectin in DM patients and DD patients and sigpatients had significantly elevated triglyceride levels.
nificantly lower adiponectin levels in DM+DD paAdditionally, our data supported the accepted trend
tients, which indicated a diminished ability to offset
that diabetes is closely associated with reduced levels
the DCM complications and progression.
of HDL.
IGFBP7 is an established marker for diabetes,
and is associated with the severity of diastolic
dysfunction [28]. IGFBP7 also has been implicated in fibrogenesis in diabetic patients, and
increasing concentrations correlate with increased collagen deposition, which, in cardiac
tissue, may contribute to diastolic stiffness
[39]. Diabetes-induced ROS generation
up-regulates the expression of the profibrotic
marker TGF-β, leading to increased extracellular matrix synthesis and fibrosis [26]. Increased collagen deposition and interstitial
fibrosis are key pathogenic components of
DCM that result in myocardial stiffness, which
manifests as diastolic dysfunction [2]. In concordance with previous studies, our data indicated elevated IGFBP7 and TGF-β levels in
DM, DD and DM+DD patients, with DM+DD
patients displaying the highest values. Therefore, these markers play an important role in
the early detection of DCM and cardiac fibroFigure 5: Schematic depicting the progression from diabetes to DCM and the role of
biomarkers to detect early stage DCM and attenuate disease progression.
sis, enabling early intervention to attenuate
disease progression.

Discussion

http://www.medsci.org
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Conclusion
In conclusion, our study identified a panel of
biomarkers that can complement echocardiographic
imaging studies to detect the diabetes-induced
changes in cardiac structure and function present at
the early stage of DCM. The progression of DCM from
subclinical diastolic dysfunction to overt heart failure,
and the associated high morbidity and mortality in
the later stage of the disease, validates the need for
reliable early diagnostic tools. The results of our clinical study can improve early diagnosis of DCM and
help successfully implement preventative strategies
that may slow or prevent development of the disease.
Our study advances the understanding of the
clinical use of biomarkers in the diagnosis of DCM in
a rural Appalachian population. Diabetes is a chronic
disease with high prevalence in West Virginia, and its
comorbidities present a significant public health concern. Therefore, West Virginia patients present the
ideal population to study strategies for earlier detection of DCM. Positive results from this study will
benefit this underserved population by enabling an
earlier and more reliable diagnosis of DCM so that
therapy can be administered in time to attenuate disease progression.
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